Tagged with

Switzerland CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players also present in the biosimilars space.   We position ourselves as a pure play, differentiated, fully vertically integrated biosimilars development…

Global The Top 20 companies on the 2021 Access to Medicines Index ranked on governance of access, research and development, and product delivery indices. Compiled by the Access to Medicine Foundation, the report measures how well the largest 20 global Big Pharma companies are making drugs and vaccines accessible to low-…

Europe The journey of EUnetHTA began back in 2004, when the European Commission and Council of Minsters requested the establishment of a sustainable European network on Health Technology Assessment (HTA) as “a political priority”, work on which was properly initiated in 2005 when a group of 35 organizations came together to…

Switzerland In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical breakthroughs, and why scientific innovation continues to motivate him.   When you have started two companies, people think that you…

Switzerland AbbVie Switzerland’s Jon Helsdingen outlines how he has led the Swiss affiliate through a full scale office move, the acquisition and integration of Allergan and the COVID-19 pandemic in a single year. Helsdingen also touches on talent acquisition challenges, the competitive Swiss market, and AbbVie’s digitalisation journey.   We have…

Global The top ten global generics and biosimilars companies according to a recent Informa Pharma Intelligence ranking for 2019. Sandoz leads the way in terms of revenues from generics, biosimilars, APIs, and OTC drugs, followed by Mylan – which recently merged with Pfizer’s Upjohn unit to form a new company, ‘Viatris’…

Europe While 2020 may have seemed like the year the world stood still for many, the pharma industry went into overdrive, working around the clock to ensure security of supply as well as develop diagnostics, treatments, and vaccines for COVID-19. Recruitment also continued apace; here four recent country manager appointees share…

France The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19 vaccine as it faces delays with its in-house product and the impact of this on the country’s global scientific standing. Also featured are the rising problem of anti-vaccine sentiment, an exclusive…

Vaccines Vaccines have been touted – and rightly so – as the most cost-effective health intervention after access to clean water. It is estimated by global health institutions that vaccines save at least three million lives every year. While tremendous progress has been made since the discovery of vaccines in the…

deloitte Vaccines       BACK TO HOME Securing Trust in the COVID-19 Supply Chain: From Development & Delivery to Acceptance & Administration Scientists have come together in an unparalleled worldwide collaboration and sharing of data to advance a COVID-19 vaccine.[1] As rollouts become reality, stakeholders from across the globe will need…

Global In November 2020, after months of delay caused by COVID-19 disruptions and a US antitrust roadblock, Mylan and Pfizer’s Upjohn generics unit finally closed a USD 12 billion merger. The combined new company, ‘Viatris’, boasts a global workforce of over 45,000, 50 manufacturing sites, and a presence in 165 countries,…

Global Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he has put in place for the business, and the key issues of manufacturing and access.   Cell and gene therapies are truly…